Immuneering

IMRX

3.8700.52% ( +0.020 )

Trading: Nov 11, 14:51:00 (EDT)

Q3 FY2026 EarningsQ3 FY26 net loss of $24.2M was wider than the $20.6M consensus, driven by a significant ramp-up in R&D spending to $20.7M. Diluted EPS of -$0.37 missed the consensus mean of -$0.31 but hit the low end of expectations. Despite the financial miss, clinical momentum is positive with MAPKeeper 301 enrollment ahead of schedule and the cash runway extended into Q4 2028.

Financial report interval: 2026.06.30 - 2026.09.30

Overview: Immuneering(IMRX) the EBIT is -25.79 M (-67.66%), Miss estimate;the EPS is -0.37 (+2.63%), Miss estimate.

Actual

YoY

Estimate

YoY

Vs estimate

YoY

Revenue

TBA--

0.00B--

----

EBITMiss expectations

-0.03B67.66%

-0.02B38.26%

-0.00B29.40%

EPSMiss expectations

-0.372.63%

-0.305719.55%

-0.064316.92%

Upcoming earnings report - Annual FY2026

Available dateMar 8, 2027

Estimate Revenue$0

Estimate EBIT-$87.75 M

Estimate EPS-$1.2616

Revenue

ActualEstimateUnit: USD

Quarterly

EBIT

ActualEstimateUnit: USD

Quarterly

Net income

ActualEstimateUnit: USD

Quarterly

EPS

ActualEstimateUnit: USD

Quarterly